Johnson & Johnson Cuts 2026 Earnings Outlook on $1 Billion Acquisition Costs
Johnson & Johnson cuts 2026 adjusted EPS guidance to $10.96–$11.11 after its $1B Firefly Bio acquisition and Sail Biomedicines partnership.
/ 1648 items
#XY↓
MiMedx Buys Sanara MedTech to Nearly Double Surgical Revenue
MiMedx agrees to buy Sanara MedTech for $35/share in a $350M cash-and-stock deal to nearly double surgical revenue. 2027 sales seen over $400M.
FDA Panel Votes 9-3 Against Capricor’s Duchenne Heart Therapy Over Weak Evidence
Final decision due Aug. 22.
FTC Sues Hims & Hers for Sharing Health Data with Meta and Snap
FTC, Utah and California sue Hims & Hers for sharing users’ health data with Meta and Snap despite privacy promises, plus deceptive billing.
GE HealthCare Beats Q2 Estimates on Record Orders, Weighs Sale of Struggling Patient Care Unit
GE HealthCare posts record 11.1% order growth and $5.3B revenue in Q2 2026, beating estimates. Stock jumps as it reviews Patient Care unit sale.
Biogen Beats Q2 Estimates as Newer Drugs Drive Growth
Biogen reports $2.74B Q2 revenue, up 3% and beating estimates. Growth products surge 24%, rare-disease drugs rise 11%.